11,715 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Capital Market Strategies LLC

Capital Market Strategies LLC acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,715 shares of the company’s stock, valued at approximately $461,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Larson Financial Group LLC boosted its stake in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after buying an additional 276 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of CRISPR Therapeutics during the 2nd quarter worth $35,000. National Bank of Canada FI increased its holdings in shares of CRISPR Therapeutics by 35.0% in the 2nd quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after purchasing an additional 220 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at about $40,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $43,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CRSP. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. JMP Securities reaffirmed a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, December 20th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Barclays lowered their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $77.93.

Insider Buying and Selling

In other news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the transaction, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 1.86 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,382 shares of company stock valued at $2,744,179. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Trading Up 6.5 %

CRSP traded up $2.68 during midday trading on Monday, hitting $43.70. The company’s stock had a trading volume of 1,419,041 shares, compared to its average volume of 1,497,464. CRISPR Therapeutics AG has a 52-week low of $38.20 and a 52-week high of $91.10. The firm has a 50-day moving average price of $46.92 and a two-hundred day moving average price of $49.24. The firm has a market cap of $3.73 billion, a P/E ratio of -15.44 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same quarter in the prior year, the business posted ($1.41) earnings per share. On average, equities analysts expect that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.